USPTO serial 79245594
KANGHONG
Reviewed by CopyMark Law Group
Reg. 5876519Status 709
- Filing date
- Status date
- Registration date
- Oct 8, 2019
- Examiner
- STINSON, JENNIFER ELLE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with KANGHONG?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
Sichuan, CN
Other trademarks owned by Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
Sichuan, CN
Other trademarks owned by Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
Sichuan, CN
Other trademarks owned by Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jennifer Sheehan Anderson
Jennifer Sheehan Anderson Bridge Intellectual Property Services143 CadyCenter, Suite 209Northville, MI 48167UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Mothproofing preparations; Radioactive substances in the nature of drugs for medical purposes; Chemico-pharmaceutical preparations for reducing blood fat; Chemico-pharmaceutical preparations for promoting sleep; Chemico-pharmaceutical preparations for sedation, anti-depression, tumor suppression; Chemico-pharmaceutical preparations for the treatment of diabetes, diseases of the central nervous system, diseases of the respiratory system, cardiovascular diseases and cancer; Chemico-pharmaceutical preparations used in eye surgery and intraocular surgery; Pharmaceutical preparations in the nature of tissues impregnated with pharmaceutical skin lotions; Depuratives for the body; Media for bacteriological cultures; Medicinal preparations for the mouth to be applied in the form of tablets; Semen for artificial insemination; Medicines for human purposes, namely, medicines for humans for the treatment or prevention of dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, stomach, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; Medicines for humans to treat or prevent diabetes, coughs, colds, influenza, headaches and allergic reactions; Vermin destroying preparations; Biochemical drug for medical purposes for the treatment of cancer and ophthalmic diseases; Suppositories; Pharmaceutical preparations in the form of liquids for the treatment of central nervous system diseases, tumors, diabetes, ophthalmic diseases; Pharmaceutical preparations in the form of liquids for the treatment of cancer; Disinfectants for hygiene purposes; Mosquito-repellent incense; Sanitary sterilizing preparations in the nature of tissues impregnated with sterilization preparations; Chemical conductors for electrocardiograph electrodes; Dental lacquer; Medicinal drinks in the nature of herb liqueurs; Pharmaceutical preparations used for the relief of pain and to reduce fever; Pharmaceutical preparations for the prevention and/or treatment of cardiovascular diseases, hemophilia, metabolic diseases, cancer, multiple sclerosis, urologic diseases, sexual dysfunction, osteoporosis, and climacteric diseases; Pharmaceutical preparations, namely, anticoagulants and platelet aggregation inhibitors; anti-infective pharmaceutical preparations; Pharmaceutical preparations, namely, ophthalmics; Pharmaceutical preparations for the treatment of ophthalmic diseases and conditions; Infusions for medical purposes for treating dermatological diseases; Gases for medical purposes; Wadding for medical purposes; Drugs for medical purposes, namely, pharmaceutical preparations for anti-depression, tumor suppression, relieving cough, reducing blood pressure; Drugs for medical purposes, namely, pharmaceutical preparations for the treatment central nervous system diseases, asthma, diabetes, respiratory system diseases, cancer, cardiovascular diseases, gastrointestinal diseases, hyperlipidaemia and hypercholesteremia; Drugs for medical purposes, namely, pharmaceutical preparations used in eye surgery and intraocular surgery; Bath preparations for medical purposes; Diagnostic agents for medical purposes; Solutions for contact lenses; Crude drugs, namely pharmaceutical preparations for the treatment of central nervous system diseases, namely hypertension, hyperlipidemia, schizophrenia and melancholia, digestive system diseases, namely dyspepsia, chronic gastritis, chronic lithogenous cholecystitis, chronic cholecystitis and gall-stone, ophthalmology system diseases, namely wet Age-related Macular Degeneration (AMD), and other diseases, namely fever, irritability, red eyes, mouth sores, sore throat, swollen gums, constipation, pharyngitis, tonsillitis, gingivitis, upper respiratory infection (URI), acute bronchitis, diabetes and nephropathy; Pharmaceutical preparations in the form of injections for the treatment of central nervous system diseases, diabetes, fundus oculi disease and cancer; Pharmaceutical preparations in the form of injections for tumor suppression; Pharmaceutical preparations in the form of injections used in eye surgery and intraocular surgery; Traditional Chinese medicines for Chinese medicinal use, namely, dried Chinese boxthorn fruits, Chinese-date, pseudo-ginseng, Chinese angelica and ginseng; Traditional Chinese medicines for Chinese medicinal use, namely, dried Chinese boxthorn fruits, Chinese-date, pseudo-ginseng, Chinese angelica and ginseng sold as a kit in a Chinese medicine bag | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
- Other trademarks owned by Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
- Other trademarks owned by Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
- Other trademarks in Class 005
- Similar marks named KANGHONG
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 24, 2026 | C71T | CANCELLED SECTION 71 | — |
| Oct 8, 2024 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jun 9, 2024 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 10, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 10, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 10, 2022 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Feb 10, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 10, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 10, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Mar 13, 2020 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 3, 2020 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Feb 3, 2020 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Jan 8, 2020 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 8, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 23, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 23, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 3, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 14, 2019 | ALIE | ASSIGNED TO LIE | — |
| May 31, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 10, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 9, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 9, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 28, 2018 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 13, 2018 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 13, 2018 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 30, 2018 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 29, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 27, 2018 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 23, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 23, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 22, 2018 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |